• About
    • Company Overview
    • Management
    • Board of Directors
    • Advisory Board
  • Collaborations
    • Partner Collaborations
    • Scientific & Research Collaborations
  • Patients
    • Patients Overview
    • Current Studies
      • Sponsored
        • TakeAim Lymphoma
        • TakeAim Leukemia
    • Understanding Primary CNS Lymphoma
    • Compassionate Use Policy
  • Pipeline
    • Pipeline Overview
    • CA-4948
    • Fimepinostat
    • CA-170
    • CA-327
  • Scientific Resources
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Committee Composition
      • Contact the Board
    • Financial Information
      • SEC Filings
      • Annual Reports
      • IRS Form 8937
    • Stock Performance
      • Historical Stock Lookup
      • Analyst Coverage
    • Contact Us
  • Careers
    • Life at Curis
    • Open Positions
    • Benefits
  • Contact
  • About
    • Company Overview
    • Management
    • Board of Directors
    • Advisory Board
  • Collaborations
    • Partner Collaborations
    • Scientific & Research Collaborations
  • Patients
    • Patients Overview
    • About Clinical Studies
    • Current Studies
      • Sponsored
        • TakeAim Lymphoma
        • TakeAim Leukemia
    • Studies Now Enrolling
  • Pipeline
    • Pipeline Overview
    • CA-4948
    • Fimepinostat
    • CA-170
    • CA-327
  • Scientific Resources
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
      • SEC Filings
      • Annual Reports
      • IRS Form 8937
    • Stock Performance
    • Contact Us
  • Careers
    • Life at Curis
    • Open Positions
    • Benefits
  • Contact

SEC Filings

NASDAQCRIS
YearTrailing 12-MonthsCalendar Year 2026Calendar Year 2025Calendar Year 2024Calendar Year 2023Calendar Year 2022Calendar Year 2021Calendar Year 2020Calendar Year 2019Calendar Year 2018Calendar Year 2017Calendar Year 2016Calendar Year 2015Calendar Year 2014Calendar Year 2013
ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Proxy & Information StatementsOther
FormDescriptionDateFormat
DEF 14AOfficial notification to shareholders of matters to be brought to a vote ("Proxy")Apr 13, 2022Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in HTML.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in DOC file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in PDF file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in XLS file.
DEFA14AAdditional proxy soliciting materials - definitiveApr 13, 2022Open Additional proxy soliciting materials - definitive in HTML.Open Additional proxy soliciting materials - definitive in DOC file.Open Additional proxy soliciting materials - definitive in PDF file.Open Additional proxy soliciting materials - definitive in XLS file.
© Curis, Inc. 2026 - All Rights Reserved
  • Terms of Use
  • Privacy Policy
  • About
    • Company Overview
    • Management
    • Board of Directors
    • Advisory Board
  • Collaborations
    • Partner Collaborations
    • Scientific & Research Collaborations
  • Patients
    • Patients Overview
    • Current Studies
      • Sponsored
        • TakeAim Lymphoma
        • TakeAim Leukemia
    • Understanding Primary CNS Lymphoma
    • Compassionate Use Policy
  • Pipeline
    • Pipeline Overview
    • CA-4948
    • Fimepinostat
    • CA-170
    • CA-327
  • Scientific Resources
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
      • SEC Filings
      • Annual Reports
      • IRS Form 8937
    • Stock Performance
    • Contact Us
  • Careers
    • Life at Curis
    • Open Positions
    • Benefits
  • Contact